Ved tidlig og fremskreden Parkinsons sygdom, var effekten af pramipexol i de kontrollerede kliniske undersøgelser bevaret i ca.
In early and advanced Parkinson’ s disease, efficacy of pramipexole in the controlled clinical trials was maintained for approximately six months.